Jamie Raskin actually said...
The investigation found that drug companies aggressively raise prices to meet revenue targets, that drug companies targeted the U.S. market for higher prices than are set in other countries, and that drug companies were engaged in anti-competitive practices to keep prices high.
Context
Raskin discusses findings on drug pricing and anti-competitive practices by pharmaceutical companies.
05/22/2023